Featured

Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo
Member News

Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo

A Joint Conference on thalassaemia by the Egyptian Thalassemia Association (ETA), the Egyptian Society of Hematology & Research (ESHR) and the Thalassaemia International Federation (TIF) will be held on 25-26…
GoCART Coalition: EHA and EBMT Join Forces To Position Europe In The Lead Of The Global Cellular Therapy Field
News

GoCART Coalition: EHA and EBMT Join Forces To Position Europe In The Lead Of The Global Cellular Therapy Field

The European Hematology Association (EHA) and the European Society of Blood and Marrow Transplantation (EBMT) announce a strategic partnership to empower Europe to become a global leader in the cellular…
PK Deficiency Resources Now Available On TIF’s Website
News

PK Deficiency Resources Now Available On TIF’s Website

Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…
Cyprus President Anastasiades Welcomed A TIF Delegation
News

Cyprus President Anastasiades Welcomed A TIF Delegation

An official meeting with the President of the Republic of Cyprus, Mr. Nicos Anastasiades, was held this morning by a delegation of the Thalassaemia International Federation, headed by the President…
Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest
News

Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest

The drug maker Pfizer announced yesterday that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly effective in preventing Covid-19, a promising development as the world…
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
Clinical News

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?

There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients
Clinical News

EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients

The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell disease (SCD). This approval follows a recommendation for conditional approval issued in July…
Back to top button